The Lancet Respiratory Medicine: Clinical trial finds inhaled immune response protein increases odds of recovery for hospitalised COVID-19 patients

(The Lancet) Hospitalised COVID-19 patients in the UK who received an inhaled form of interferon beta-1a (SNG001) were more likely to recover and less likely to develop severe symptoms than patients who received a placebo, according to a new clinical trial published inThe Lancet Respiratory Medicine journal.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news